We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
+3.29%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$43.8B
AUM Growth
+$2.95B
(+7.2%)
Cap. Flow
+$2.92B
Cap. Flow
% of AUM
6.68%
Top 10 Holdings %
Top 10 Hldgs %
29.71%
Holding
2,321
New
255
Increased
1,689
Reduced
325
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$408M |
| 2 |
NVIDIA
NVDA
|
+$395M |
| 3 |
Microsoft
MSFT
|
+$382M |
| 4 |
Amazon
AMZN
|
+$253M |
| 5 |
Palantir
PLTR
|
+$148M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$285M |
| 2 |
NextEra Energy
NEE
|
+$207M |
| 3 |
West Pharmaceutical
WST
|
+$168M |
| 4 |
Broadcom
AVGO
|
+$133M |
| 5 |
Meta Platforms (Facebook)
META
|
+$128M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.42% |
| 2 | Consumer Discretionary | 10.78% |
| 3 | Consumer Staples | 10.15% |
| 4 | Industrials | 10.05% |
| 5 | Financials | 9.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2251
Roadzen
RDZN
$101M
| $23.2K | ﹤0.01% |
+10,633
| New | +$13.1K |
|
2252
Nautilus Biotechnolgy
NAUT
$215M
| $23.1K | ﹤0.01% |
13,721
-2,895
| -17% | -$6.92K |
|
2253
Tenaya Therapeutics
TNYA
$168M
| $22.1K | ﹤0.01% |
15,440
+5,018
| +48% | +$11.2K |
|
2254
Lineage Cell Therapeutics
LCTX
$257M
| $20.9K | ﹤0.01% |
41,606
+13,691
| +49% | +$10.1K |
|
|
CLYM
2255
Climb Bio
CLYM
$735M
| $20.6K | ﹤0.01% |
+11,469
| New | +$41.5K |
|
2256
Acumen Pharmaceuticals
ABOS
$154M
| $20.3K | ﹤0.01% |
+11,812
| New | +$28.4K |
|
|
NOTE
2257
DELISTED
FiscalNote
NOTE
| $18.9K | ﹤0.01% |
1,472
+524
| +55% | +$6.38K |
|
2258
Ovid Therapeutics
OVID
$435M
| $15.5K | ﹤0.01% |
16,584
+1,263
| +8% | +$1.41K |
|
2259
Tevogen Bio Holdings
TVGN
$18.9M
| $15.1K | ﹤0.01% |
+294
| New | +$19.2K |
|
|
GBIO
2260
DELISTED
Generation Bio
GBIO
| $14.8K | ﹤0.01% |
+1,393
| New | +$24.8K |
|
2261
Shattuck Labs
STTK
$710M
| $13.3K | ﹤0.01% |
+11,016
| New | +$13.6K |
|
2262
Century Therapeutics
IPSC
$381M
| $13.3K | ﹤0.01% |
+13,180
| New | +$17.9K |
|
2263
374Water
SCWO
$37.8M
| $12.6K | ﹤0.01% |
1,840
+605
| +49% | +$7.46K |
|
2264
Purple Innovation
PRPL
$33.2M
| $12.5K | ﹤0.01% |
641
+211
| +49% | +$4.77K |
|
2265
Invivyd
IVVD
$180M
| $9.9K | ﹤0.01% |
22,336
+7,352
| +49% | +$5.72K |
|
2266
Solidion Technology
STI
$56.1M
| $9.76K | ﹤0.01% |
+280
| New | +$5.82K |
|
|
AMRN
2267
Amarin Corp
AMRN
$284M
| $9.2K | ﹤0.01% |
948
-234
| -20% | -$2.51K |
|
|
ELEV
2268
DELISTED
Elevation Oncology
ELEV
| $8.94K | ﹤0.01% |
+15,894
| New | +$9.38K |
|
2269
MarketWise
MKTW
$53.1M
| $6.27K | ﹤0.01% |
+552
| New | +$6.16K |
|
|
LYRA
2270
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $2.81K | ﹤0.01% |
+273
| New | +$3K |
|
2271
CDT Equity Inc
CDT
$1.93M
| – | – |
0
| – | – |
|
2272
Acadia Healthcare
ACHC
$3.17B
| – | – |
-4,321
| Closed | -$274K |
|
|
APLS
2273
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-7,197
| Closed | -$208K |
|
|
AUTL
2274
Autolus Therapeutics
AUTL
$386M
| – | – |
-11,796
| Closed | -$42.8K |
|
2275
Bath & Body Works
BBWI
$4.01B
| – | – |
-41,141
| Closed | -$1.31M |
|
Similar funds
ProShare Advisors's Q4 2024 Portfolio in Review
As of Q4 2024, ProShare Advisors held 2,321 positions worth $43.8B, up 7.2% from $40.8B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
ProShare Advisors deployed $2.92B of net new capital in Q4 2024, opening 255 new positions and adding to 1,689 existing holdings. Its largest new stake was Applovin: 338,942 shares worth $110M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 29% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was Walmart Inc, an estimated $285M trimmed.
- ProShare Advisors's largest Q4 2024 buy was Applovin: 338,942 shares worth $110M.
- ProShare Advisors added most to Apple in Q4 2024, an estimated $408M increase.
- ProShare Advisors's biggest Q4 2024 reduction was Walmart Inc, cutting an estimated $285M.
- ProShare Advisors fully exited PetIQ, Inc. Class A Common Stock in Q4 2024, selling an estimated $3.25M.
- ProShare Advisors's ten largest holdings make up 30% of its $43.8B portfolio in Q4 2024.
- ProShare Advisors opened 255 new positions and closed 50 in Q4 2024.
- ProShare Advisors's portfolio value rose 7.2% quarter-over-quarter to $43.8B.
Based on ProShare Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.